Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: The norepinephrine transporter in the brain has been targeted in the treatment of psychiatric disorders. Duloxetine is a serotonin and norepinephrine reuptake inhibitor that has been widely used for the treatment of depression. However, the relationship between dose and plasma concentration of duloxetine and norepinephrine transporter occupancy in the human brain has not been determined. In this study, we examined norepinephrine transporter occupancy by different doses of duloxetine. Methods: We calculated norepinephrine transporter occupancies from 2 positron emission tomography scans using (S,S)-[18F]FMeNER-D2 before and after a single oral dose of duloxetine (20 mg, n = 3; 40 mg, n = 3; 60 mg, n =2). Positron emission tomography scans were performed from 120 to 180 minutes after an i.v. bolus injection of (S,S)-[18F]FMeNER-D2. Venous blood samples were taken to measure the plasma concentration of duloxetine just before and after the second positron emission tomography scan. Results: Norepinephrine transporter occupancy by duloxetine was 29.7% at 20 mg, 30.5% at 40 mg, and 40.0% at 60 mg. The estimated dose of duloxetine inducing 50% norepinephrine transporter occupancy was 76.8 mg, and the estimated plasma drug concentration inducing 50% norepinephrine transporter occupancy was 58.0 ng/mL. Conclusions: Norepinephrine transporter occupancy by clinical doses of duloxetine was approximately 30% to 40% in human brain as estimated using positron emission tomography with (S,S)-[18F]FMeNER-D2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As SSRIs, SNRIs, and serotonin modulators are not selective to SERT [49–52]”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pietrzak, R. H., Gallezot, J.-D., Ding, Y.-S., Henry, S., Potenza, M. N., Southwick, S. M., Krystal, J. H., Carson, R. E., & Neumeister, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.399 · Cited by 127
RetractedTzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848 · cited 2×
“The norepinephrine systems play important roles in various psychiatric disorders (Biederman and Spencer, 1999; Sara, 2009; Pietrzak et al., 2013).”
BackgroundBymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Self-citationAttention-deficit/hyperactivity disorder (adhd) as a noradrenergic disorder
Biederman, J., & Spencer, T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00192-4 · Cited by 513
Prediction of Tricyclic Antidepressant Response: A Critical Review
Bielski, R. J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770120083009 · Cited by 349
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Self-citationPapakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Duloxetine: Clinical Pharmacokinetics and Drug Interactions
Knadler, M. P., Lobo, E., Chappell, J., & Bergstrom, R. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539240-000000000-00000 · Cited by 237
Meta-analysis of molecular imaging of serotonin transporters in major depression
Gryglewski, G., Lanzenberger, R., Kranz, G. S., & Cumming, P. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.82 · Cited by 227 · cited 14×
“This approach, along with previous PET assays, allows the clarification of relationships between occupancies of NET and SERT by selective and nonselective inhibitors providing antidepressant effects.”
BackgroundInfluential(2006) · PubMed · Cited by 207
Duloxetine for the Treatment of Major Depressive Disorder
Nemeroff, C. B., MD, PhD, Schatzberg, A. F., MD, Goldstein, D. J., MD, PhD, Detke, M. J., MD, et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4207 · Cited by 175
Duloxetine versus other anti-depressive agents for depression
Cipriani, A., Koesters, M., Furukawa, T. A., Nosè, M., Purgato, M., Omori, I. M., Trespidi, C., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006533.pub2 · Cited by 165
Schou, M., Halldin, C., Sóvágó, J., Pike, V. W., Hall, H., Gulyás, B., Mozley, P. D., Dobson, D., Shchukin, E., Innis, R. B., et al. (2004) · Synapse · doi:10.1002/syn.20031 · Cited by 129
A dose-finding study of duloxetine based on serotonin transporter occupancy
Takano, A., Suzuki, K., Kosaka, J., Ota, M., Nozaki, S., Ikoma, Y., Tanada, S., & Suhara, T. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0304-0 · Cited by 110 · cited 15×
“This approach, along with previous PET assays, allows the clarification of relationships between occupancies of NET and SERT by selective and nonselective inhibitors providing antidepressant effects.”
BackgroundSelf-citationGulyás, B. Z., Brockschnieder, D., Nag, S., Pavlova, E. L., Kása, P., Beliczai, Z., Légrádi, Á., Gulya, K., Thiele, A., Dyrks, T., et al. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.03.001 · Cited by 83
Norepinephrine Transporter in Major Depressive Disorder: A PET Study
Moriguchi, S., Yamada, M., Takano, H., Nagashima, T., Takahata, K., Yokokawa, K., Ito, T., Ishii, T., Kimura, Y., Zhang, M.-R., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15101334 · Cited by 72
Self-citationAbanades, S., van der Aart, J., Barletta, J. A., Marzano, C., Searle, G. E., Salinas, C. A., Ahmad, J. J., Reiley, R. R., Pampols-Maso, S., Zamuner, S., et al. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.175 · Cited by 61
Arakawa, R., Okumura, M., Ito, H., Seki, C., Takahashi, H., Takano, H., Nakao, R., Suzuki, K., Okubo, Y., Halldin, C., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.051292 · Cited by 50
Self-citationThe Influence of Smoking on the Serum Level of Duloxetine
Fric, M., Pfuhlmann, B., Laux, G., Riederer, P., Distler, G., Artmann, S., Wohlschläger, M., Liebmann, M., & Deckert, J. (2008) · Pharmacopsychiatry · doi:10.1055/s-2008-1073173 · Cited by 47
Nogami, T., Takano, H., Arakawa, R., Ichimiya, T., Fujiwara, H., Kimura, Y., Kodaka, F., Sasaki, T., Takahata, K., Suzuki, M., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001009 · Cited by 46
Self-citationSekine, M., Arakawa, R., Ito, H., Okumura, M., Sasaki, T., Takahashi, H., Takano, H., Okubo, Y., Halldin, C., & Suhara, T. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1824-9 · Cited by 39
Self-citationTakano, H., Arakawa, R., Nogami, T., Suzuki, M., Nagashima, T., Fujiwara, H., Kimura, Y., Kodaka, F., Takahata, K., Shimada, H., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001521 · Cited by 34
Self-citationPET Quantification of the Norepinephrine Transporter in Human Brain with (S,S)-18F-FMeNER-D2
Moriguchi, S., Kimura, Y., Ichise, M., Arakawa, R., Takano, H., Seki, C., Ikoma, Y., Takahata, K., Nagashima, T., Yamada, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178913 · Cited by 30
Self-citationSchou, M., Pike, V. W., & Halldin, C. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607782507411 · Cited by 21
Takano, A., Halldin, C., Varrone, A., Karlsson, P., Sjöholm, N., Stubbs, J. B., Schou, M., Airaksinen, A. J., Tauscher, J. T., & Gulyás, B. Z. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0622-z · Cited by 20
Bourdet, D. L., Tsuruda, P. R., Obedencio, G. P., & Smith, J. A. M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.188417 · Cited by 16
Research works printed but not linked: 1
- Eli Lilly and Company, 2017, Cymbalta(R)
Cited by
Jesulola, E., Micalos, P., & Baguley, I. J. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.12.025 · Cited by 379
Arakawa, R., Stenkrona, P., Takano, A., Svensson, J., Andersson, M., Nag, S., Asami, Y., Hirano, Y., Halldin, C., & Lundberg, J. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz003 · Cited by 70
Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01285-w · Cited by 65
Adaptation of Lipid Profiling in Depression Disease and Treatment: A Critical Review
Pinto, B., Conde, T., Domingues, I., & Domingues, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042032 · Cited by 51
“In fact, some studies have found associations between changes in 5HT levels, as well as NE and DA, and behavioral aspects including appetite, sleep, pain response, and circadian rhythm, all of which are linked to MDD [33,34].”
BackgroundEap, C. B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M., de León, J., Greiner, C., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1878427 · Cited by 57
Self-citation
Metadata
- Authors
- Moriguchi, S., Takano, H., Kimura, Y., Nagashima, T., Takahata, K., Kubota, M., Kitamura, S., Ishii, T., Ichise, M., Zhang, M.-R., Shimada, H., Mimura, M., Meyer, J. H., Higuchi, M., & Suhara, T.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- Corresponding author
- Moriguchi, Sho
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-03
- Volume
- 20
- Issue
- 12
- Pages
- 957-962
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5716070
- OpenAlex
- W2743543212
- Cited by
- 47
- References
- 28
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2022: 2 · 2021: 25 · 2020: 2 · 2019: 5 · 2017: 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Funders
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science (16H05324)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- norepinephrine transporter, duloxetine, PET radiotracer, dose-response relationship, plasma drug concentration, serotonin-norepinephrine reuptake inhibitors, depression treatment, brain norepinephrine
- MeSH terms
- Duloxetine Hydrochloride, Adult, Antidepressive Agents, Brain, Dose-Response Relationship, Drug, Fluorine Radioisotopes, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Morpholines, Protein Binding, Positron-Emission Tomography, Norepinephrine Plasma Membrane Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
